ClinicalTrials.gg
RecruitingNCT07449572Updated Sep 16, 2026

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

A Phase 1 interventional study of HT31-1 and Saline (0.9%, sterile, for infusion) in ARDS (Acute Respiratory Distress Syndrome), sponsored by HTIC, Inc. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by HTIC, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.

Planned enrollment
58th of 88
24 · median 68
Started
2026
with 5 others
Phase 1
10 of 112
1 open now
Primary completion
2027-01
later than 3 of 18 live
Registered
107th of 112
by date

Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 58th largest by planned enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 3 of the 18 other live ones, and was the 107th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Acute Lung Injury with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunteers and in patients with mild-to-moderate acute respiratory distress syndrome (ARDS) due to an infectious source.

The current trial (Part A) focuses on single ascending doses (SAD) in healthy volunteers to characterize the safety profile, PK parameters, and immunogenicity of HT31-1. Emerging data from this phase will inform dose selection for the subsequent Part B study in ARDS patients and help establish the recommended Phase 2 dose (RP2D). Additionally, exploratory pharmacodynamic and biomarker assessments will be performed to evaluate target engagement and potential early biological activity.

Read the detailed description

HT31-1 injection is a first-in-class humanized monoclonal antibody that neutralizes citrullinated histone H3 (CitH3), a critical damage-associated molecular pattern (DAMP) driving neutrophil extracellular trap (NETosis-induced endothelial injury, microvascular thrombosis, and hyper-inflammation in sepsis and ARDS. HT31-1 addresses the underlying pathophysiology of sepsis/ARDS without impacting the innate immune defense function, thus provide a potentially safe and effective means to treat ARDS.

Design: Randomized, double-blind, placebo-controlled, single ascending dose (SAD) study.

Cohort size: 8 participants per cohort (6 assigned to HT31-1 and 2 assigned to placebo).

Randomization: 3:1 ratio (HT31-1: placebo). Blinding: HT31-1 and placebo will be provided as identical, indistinguishable investigational products supplied by the Investigational Pharmacy. Both participants and all study site personnel (including investigators, study staff, and safety assessors) will remain blinded to treatment allocation. Randomization codes will be maintained by an independent statistician or designated unblinded party and will not be disclosed until database lock unless required for subject safety.

Population: Approximately 24 healthy adult volunteers.

Dosing:

A single intravenous infusion of HT31-1 per cohort at ascending dose levels of 1 mg/kg, 5 mg/kg, and 20 mg/kg. Dose escalation will proceed in a sentinel dosing format with interim safety reviews between cohorts.

Each cohort will enroll 8 participants (6 HT31-1, 2 placebo). A total of up to 24 participants will be enrolled in Part A. No additional expansion cohort is planned.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)

Keywords

  • Acute Respiratory Distress Syndrome (ARDS)
  • Single Ascending Dose
  • Monoclonal Antibody
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

  1. Age 18 to 65 years old, inclusive, at the time of consent.
  2. Able and willing to provide written and to comply with all study procedures and requirements.
  3. Healthy as determined by medical history, physical examination, and baseline investigations. No abnormalities on physical exam.
  4. (BMI) between 18.0 and 32.0 kg/m², inclusive.
  5. Vital signs and 12-lead without clinically significant abnormalities, in the investigator's judgment, at screening (e.g., resting blood pressure and heart rate within normal limits).
  6. Screening clinical laboratory tests (hematology, chemistry, liver and kidney function, etc.) within normal ranges or not clinically significant as judged by the investigator.
  7. Female volunteers must be of non- (either surgically sterile by tubal ligation, bilateral oophorectomy or hysterectomy at least 6 months prior, or for ≥1 year) OR if of childbearing potential must agree to use 2 approved effective contraceptions from screening through at least 90 days after the last dose. Acceptable methods include hormonal , intrauterine device, or barrier methods with spermicide.
  8. Male volunteers with partners of childbearing potential must agree to use 2 approved effective contraception (e.g., condom plus spermicide) from screening through 90 days after their dose of study drug.
  9. Able to communicate well with the investigator and comply with study requirements (e.g., availability for all follow-up visits).

Exclusion criteria

Exclusion Criteria:

Participants will be excluded if they meet any of the following criteria:

  1. History of any severe allergy or to drugs, or known hypersensitivity to any monoclonal antibody (including prior biologic therapy reactions).
  2. Known disease or immunodeficiency condition, including a positive test for at screening.
  3. Active or chronic viral hepatitis infection: positive screening test for surface antigen (HBsAg) or antibody.
  4. History of tetanus infection, or receipt of tetanus toxoid vaccine within 6 months prior to first dose of study drug. (Rationale: CitH3 is associated with NETs, and recent tetanus immunization may confound immune status or antibody responses).
  5. Receipt of any within 4 weeks prior to first dose, or any inactivated vaccine within 2 weeks prior to first dose. (This is to avoid confounding immune activation or risk to the volunteer's health).
  6. History of any significant acute or chronic illness that, in the investigator's opinion, could interfere with the trial or pose additional risk in administering the drug. Examples include significant cardiovascular, hepatic, renal, gastrointestinal, hematologic, neurologic, psychiatric, or respiratory conditions that are not well-controlled.
  7. Recent major surgery (within 3 months prior to screening) or planned elective surgery during the study period. (Minor outpatient procedures are allowed at the investigator's discretion.)
  8. Difficulty with venous access or an inability to tolerate blood draws, such that required PK sampling would be compromised.
  9. History of drug or alcohol abuse: positive urine drug screen at screening for illicit substances, or a history of significant drug abuse in the past 5 years. Regular use of cannabis is also exclusionary unless stopped prior to study.
  10. Positive screening alcohol breath test, or history of excessive alcohol intake (more than \~14 units per week; 1 unit = 360 mL beer, 150 mL wine, or 45 mL of 40% spirit) within 6 months. Any indication of alcoholism or inability to refrain from alcohol during study participation.
  11. Use of any prescription or over-the-counter medications, herbal remedies, or supplements within 14 days prior to first dose, except hormonal or occasional acetaminophen. (Any necessary medications may be reviewed by the investigator for approval if unlikely to interfere with study outcomes).
  12. Participation in another clinical trial of an investigational drug or device within 4 weeks (or 5 half-lives of that investigational product, whichever is longer) prior to dosing.
  13. Donation of >400 mL of blood (or significant blood loss of similar volume) within 3 months prior to screening, or donation of >200 mL within 1 month prior. (This is to avoid anemia or confounding volume loss).
  14. Receipt of any blood products or immunoglobulin therapy within 90 days before dosing.
  15. Chronic use of medications (systemic , immunomodulators) within 45 days before dosing (inhaled/topical steroids for mild conditions may be permitted).
  16. Regular use of nicotine products (smoking more than 5 cigarettes per day or equivalent) within 3 months prior to screening, or inability to refrain from tobacco/nicotine during the study.
  17. Pregnant or breastfeeding women. (Female volunteers must have a negative pregnancy test and not be nursing.)
  18. Any other condition that, in the opinion of the investigator, makes the volunteer unsuitable for study participation (e.g. inability to comply with protocol, or any factor that would jeopardize the volunteer's safety or the validity of the data).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1: 1 mg/kg

    HT31-1 1mg/kg single intravenous dosing

    Drug: HT31-1

  • Placebo comparator
    Cohort 1: Placebo

    Saline single intravenous dosing

    Other: Saline (0.9%, sterile, for infusion)

  • Experimental
    Cohort 2: 5 mg/kg

    HT31-1 5mg/kg single intravenous dosing

    Drug: HT31-1

  • Placebo comparator
    Cohort 2: Placebo

    Saline single intravenous dosing

    Other: Saline (0.9%, sterile, for infusion)

  • Experimental
    Cohort 3: 20 mg/kg

    HT31-1 20mg/kg single intravenous dosing

    Drug: HT31-1

  • Placebo comparator
    Cohort 3: Placebo

    Saline single intravenous dosing

    Other: Saline (0.9%, sterile, for infusion)

Interventions

  • DrugHT31-1

    HT-1 is a humanized monoclonal antibody developed by HTIC, Inc as a treatment for Acute Respiratory Distress Syndrome (ARDS) Due to an Infectious Source

    Also known as: hCitH3-mAb, humanized anti-citrullinated histone H3 monoclonal antibody

  • OtherSaline (0.9%, sterile, for infusion)

    Saline is as placebo control

    Also known as: Placebo control

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The number and percentage of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) following administration of HT31-1.

    Time frame: 0-28 days

  2. Assess dose-limiting toxicities (DLTs)

    Number and percentage of participants experiencing DLTs at each dose level.

    Time frame: 0-28 days

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    Maximum observed plasma concentration (Cmax) of HT31-1 following single intravenous administration.

    Time frame: From pre-dose through Day 28 post-dose

  2. Time to maximum concentration (Tmax)

    Time to reach the maximum observed plasma concentration (Tmax) of HT31-1 following single intravenous administration.

    Time frame: From pre-dose through Day 28 post-dose

  3. Area under the curve (AUC)

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t )and from time zero extrapolated to infinity (AUC0-∞) of HT31-1 following single intravenous administration.

    Time frame: From pre-dose through Day 28 post-dose

  4. Half-life (t1/2)

    Time for serum concentration to decrease by half in the terminal phase.

    Time frame: From pre-dose through Day 28 post-dose

  5. Clearance (CL)

    Volume of plasma cleared of drug per unit time (mL/hr or L/day).

    Time frame: From pre-dose through Day 28 post-dose

  6. Volume of distribution (Vd)

    Volume of distribution (Vd) of HT31-1 following single intravenous administration.

    Time frame: From pre-dose through Day 28 post-dose

  7. Assess preliminary pharmacodynamic (PD) effects

    Measurable changes in circulating CitH3 levels following either HT31-1 or placebo administration.

    Time frame: From pre-dose through Day 28 post-dose

Other outcomes

  1. Incidence of Anti-Drug Antibodies (ADA)

    Incidence of treatment-emergent anti-drug antibodies (ADA) against HT31-1.

    Time frame: From pre-dose through Day 28 post-dose

  2. Titer of Anti-Drug Antibodies (ADA)

    Titer of treatment-emergent anti-drug antibodies (ADA) against HT31-1.

    Time frame: From pre-dose through Day 28 post-dose

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Weber M, Chen Y, Zhou X, Chun H, Wu D, Park KH, Cai C, Li Y, Ma J, Yang Z. Humanized Monoclonal Antibody Against Citrullinated Histone H3 Attenuates Myocardial Injury and Prevents Heart Failure in Rodent Models. Biomolecules. 2025 Aug 20;15(8):1196. doi: 10.3390/biom15081196. PubMed 40867640 ↗
  • Ouyang W, Chen Y, Tan T, Song Y, Dong T, Yu X, Lee KE, Zhou X, Tetz Z, Go S, Zeng X, Shao L, Quan C, Zhao T, Tian Y, Kurabayashi K, Jin H, Ma J, Qin J, Williams B, Li Q, Zhu GD, Alam HB, Stringer KA, Li Y, Ma J. A citrullinated histone H3 monoclonal antibody for immune modulation in sepsis. Nat Commun. 2025 Aug 12;16(1):7435. doi: 10.1038/s41467-025-62788-6. PubMed 40796783 ↗
  • Aziz DZ, Binion CC, Xu H, Wang X, Rodgers S, Gillis DC, Ledford BT, Siletzky R, Zhou X, Li Y, Cai C, Tsihlis ND, Ma J, Kibbe MR. Humanized Citrullinated Histone H3 Monoclonal Antibody Improves Respiratory Function and Attenuates Neutrophil-Mediated Inflammation in a Rodent Model of Smoke Inhalation Lung Injury. J Am Coll Surg. 2026 Jan 1;242(1):1-12. doi: 10.1097/XCS.0000000000001620. Epub 2025 Dec 17. PubMed 41051091 ↗

Related links

Individual participant data

Plan to share: No — Individual participant data will not be shared because this is an early-phase study with a small number of participants, and sharing data could risk participant re-identification.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Mar 4, 2026
StartActual
May 28, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07449572
Lead sponsor
HTIC, Inc
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
May 28, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Lacey Harris, MPH, BSN
Contact
Lacey.Harris@vcuhealth.org
804-828-0404
Jianjie Ma, PhD
study director · HTIC, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion